Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving…

By E. Keystone, A. Kavanaugh, J. Sharp, H. Tannenbaum, Y. Hua, L. Teoh, S. Fischkoff, E. Chartash. Arthritis & Rheumatism, 2004

1,272 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, background): “In T-cell responses to antigen, TNFR2 is functionally linked to CD28 and has a critical role in IL-2 induction and T-cell survival (Kim and Teh, 2004).”
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010, neutral): “This was also concluded in a recent meta-analysis devoted to this issue.”
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis (2020, background): “elevated at twice the normal range in placebo-controls [233].”
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. (2006, result): “Our findings of a significant increase in serious infections in patients treated with TNF antagonists is consistent with current knowledge of the biological actions of TNF and its role combating infections(2-4) and with findings of large observational studies and randomized controlled trials includi”